Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a $20 price target.
September 26, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences (NASDAQ:CHRS) has been reiterated with a 'Buy' rating by Truist Securities, maintaining a $20 price target.
The 'Buy' rating from Truist Securities indicates a positive outlook for Coherus BioSciences. The maintained price target of $20 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100